Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Transcript (slightly modified)
What are the advantages of digital delivery of a chronic disease management program, compared with an in-person program?
I think they’re both very important. They’re both excellent ways of bringing research-proven approaches to help people self-manage their conditions. Digital has certain advantages over in-person, and in-person has advantages over digital.
Digital is ubiquitous, 24/7, the person doesn’t need to get in their car to get to the appointment, they can access it from the privacy of their home, they can come on for 5 or 10 minutes if that’s all they have that day, or they can spend an hour or longer if need be. It identifies and helps people who don’t like to join groups. Many people are not happy with that approach; they want to be anonymous in their conversations.
In-person is in-person, and it allows you to have a more intimate relationship with individuals who come to your group. It has benefits where individuals are able to share and have that direct social support. Digital provides indirect social support, and depending on the individual, some approaches work better than others.
In-person has a challenge, in that you have to get people to show up at the same time, at the same place, an hour a week or more depending on the program, and that can have some significant logistics challenges.
So, I actually believe that the future will have combined approaches where individuals will be given the choice between a digital delivery of that program, in this case a diabetes prevention program or a chronic disease self-management program, and also in-person delivery of those same programs.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen